The in vitro and in vivo antibacterial activities of6-0-methylerythromycin A (TE-03 1 , A-56268, or clarithromycin) and 6, 1 1-di-O-methylerythromycin A (TE-032) have been compared with those of erythromycin A (EM) andjosamycin (JM). TE-03 1 and TE-032, having the same antibacterial spectra as EM,are active against aerobic Gram-positive bacteria, someGram-negative bacteria, anaerobic bacteria, L-form bacteria and Mycoplasma pneumoniae. The activity of TE-03 1 against clinical isolates is equal to or two times more potent than that of EM,whereas TE-032is slightly less active than EM. The activities of TE-031 and TE-032 are pH dependent (more active at pH 8 than at 5) and are increased by adding serum to medium. TE-031 and TE-032 show dose-related bactericidal activities against Haemophilusinfluenzae. The therapeutic efficacies of TE-03 1 and TE-032against systemic and subcutaneous infections provoked by Gram-positive bacteria in mice are 4-to 35-fold superior to those of EMand JM. TE-031 and TE-032 have demonstrated higher and longer-lasting plasma levels than EMwhen administered orally to mice, rats or dogs.
suspended in physiological saline containing 5%gum arabic for po administration in vivo tests. For iv injection of drugs, the test drugs were suspended in distilled water and then dissolved by the addition of the required amount of dilute hydrochloric acid keeping pH over 7.
Susceptibility Studies
Antibiotic susceptibility was determined by an agar dilution technique using Sensitivity Test Agar (STA, Eiken) as a basal test medium. This mediumwas supplemented with 5%horse blood for Streptococcus pyogenes and Streptococcus pneumoniae, and with heat inactivated 5% horse blood for Haemophilus influenzae and Neisseria gonorrhoeae. GAMAgar (Nissui) was used for anaerobic bacteria. Brain Heart Infusion Broth (Eiken) was supplemented with agar 1%, horse serum 10%, NaCl 4% and yeast extract 0.5% for L-form bacteria. PPLOBroth (Eiken) was supplemented with agar 1%, malt extract 0.2% and horse serum 20%for Mycoplasmapneumoniae. Inoculum sizes were 106cfu/ml for both aerobic and anaerobic bacteria and 105cfu/plate for M.pneumoniae. Each serial dilution of the test drugs was mixed with the medium.The overnight culture broths of bacteria or their dilutions were seeded onto agar plates with a spot replicating device. MICend point, which is defined as the lowest antibiotic concentrations showing less than four colonies per spot, was read after 18 hours incubation for aerobic bacteria, 48 hours incubation for anaerobes and 7 days incubation for M. pneumoniae. All incubations were at 37°C.
Effect of Various Factors on Antibacterial Activity
The effects of pHof the medium, inoculum size and addition of horse serum on the antibacterial activities were assayed by determining the MICsof test drugs against Staphylococcus aureus 209P-JC, Staphylococcus epidermidis IID 866, S. pneumoniae IID 553, Bacillus subtilis ATCC6633, and Escherichia coli NIHJ JC-2 by use of STA as a basal test medium. The pH of the medium was adjusted to 8, 7, 6 or 5 with 1 n NaOHor 1 n HC1. Horse serum was added to the mediumto obtain a final serum concentration of 20%. Inoculum sizes tested were 109, 108, 107, 106 and 105cfu/ml.
Time-kill Curve Studies
The bactericidal activities of TE-031, TE-032, EMand JM over time against S. aureus Smith 4 and H. influenzae IID 984 were measured in Sensitivity Test Broth (Eiken). The medium was supplemented with 5%Fildes enrichment for H. influenzae. An overnight culture of each strain was seeded into an appropriate broth and incubated at 37°C. When the bacteria were grown to a concentration of 105~106 cells/ml, one-fourth to 4-fold the MIC of test drug was added. The number of viable cells was counted at 2, 4, 6> 8 and 24hours after the addition of drugs. For counting bacteria, STA and STA supplemented with heat inactivated 5% horse blood were used as the media for S. aureus and H. influenzae, respectively.
In Vivo Therapeutic Activity Acute Systemic Infection: Male ICR mice, 4 weeks of age, were infected intraperitoneally with 0.5 ml of a bacterial suspension containing 100%or more of minimal lethal doses of bacteria. Hog gastric mucin (5%, w/v) was added to the suspensions of organisms before injection. The test drugs in 5%gum arabic were administered orally in 0.2 ml volumes to groups of 20 mice at 1 hour after the inoculation. Mortality of the animals was recorded daily over a period of 5 to 7 days and the ED50values were calculated by the methods of probit5) or Van der Waerden.6) Subcutanous Infection: Male ddY mice, 4 weeks of age, were infected subcutaneously with 0.2 ml of the suspension containing 5 x 107 cfu/ml of S. aureus BB into the dosal area. The drugs were administered orally 1 hour after inoculation. A diameter of absess was measured at 48hours after the infection. The amount of drug (mg/mouse) required for a 50% reduction of the diameter of abscess (ID50) as compared with untreated controls was estimated.
Determination of Plasma Level
The antibiotics were administered orally or intravenously to animals. Plasmas were collected at regular time intervals after administration and the concentrations of the antibiotic were measured by the bioassay method using Micrococcus luteus ATCC9341 as a test organism. Animals used and the doses (route) of drug administration were as follows: Male ICR mice, lOOmg/kg (po); male Wister rats, 50mg/kg (po) and lOmg/kg (iv); male New Zealand White rabbits, lOmg/kg (iv); male Beagle dogs, lOmg/kg (po and iv) and 2mg/kg (iv).
Results

In Vitro Susceptibility Studies
Antibacterial Spectrum
In vitro activities (MICs) of TE-031 and TE-032 were compared with those of EMand JM against standard strains of bacteria. The results are shown in Tables 1, 2 and 3. The potency of TE-031 is generally equal to or 2-fold greater than that of EMand 2-to 8-fold greater than that of JM against aerobic Gram-positive bacteria, including S. aureus, S. epidermidis and S. pneumoniae; the potency of TE-032 against these organisms is equal to or 2-fold less than that of EM. The MICs against the EM-sensitive organisms ranged from^0.012 to 0.10^g/ml for TE-031 and from^0.012 to 0.39/ig/ml for TE-032. TE-031 and TE-032 were found to be inactive against EM-resistant strains which were sensitive to JM ( Table 1 ). The potency of TE-031 against N. gonorrhoeae (MIC 0.10/ig/ml) and H. influenzae (MIC 6.25/jg/ml) was similar to that of EM and greater than that of JM, while TE-032 was 2-to 4-fold less active than EMagainst these organisms (Table 2 ). TE-031 had approximately 2-fold more potent activity than EMagainst Gram-positive anaerobes and Bacteroides; the MICsof TE-031 against these organisms were^0.012-1.56/Jg/ml and 0.05~1.56jug/ml, respectively. The potency of TE-032 was equal to or less than that of EMagainst these organisms (Table 3) . TE-031 and TE-032 had low activities against E. coli, Klebsiella, Proteus, Pseudomonas and Fusobacterium as low as EM (Tables 2 and 3 ). Table 4 shows the activities of TE-031 and TE-032 against L-forms of S. aureus, S. pyogenes and E. coli. The activity of TE-031 (MIC 0.05-0.10jug/ml) against these bacteria was 2-to 4-fold and 4-to 8-fold more active than those of EMand JM, respectively, whereas the activity of TE-032 was equal to that of EMagainst these bacteria.
Susceptibility of Clinical Isolates
The in vitro antibacterial activities of TE-031 and TE-032, compared with EMand JM, were tested against 198 strains of clinical isolates, including S. aureus (48), S. epidermidis (50), Enterococcus faecalis (45), S. pyogenes (1 1), S. pneumoniae (10), H. influenzae (19) and Mycoplasma pneumoniae (15). As shown in Table 5 , the potency of TE-031 was equal to or slightly greater than that of EMagainst all groups of test organisms, whereas TE-032 was 2-fold less potent than EM.In particular, TE-031 was effective against 100% of all the isolates, for S. pneumoniae (MICfg0.012~0.05/zg/ml), S. pyogenes (MIC^0.012-0.05 /ig/ml), M. pneumoniae (MIC 0.0020-0.0156/xg/ml), H. influenzae (MIC 1.56-6.25 jug/ml); the MICs50 of TE-031 against these organisms were^0.012, 0.025, 0.0078 and 3.13/ig/ml, Inoculum size: 106 cfu/ml. Medium: GAMAgar (Nissui). respectively. TE-031, TE-032 and EM showd no potency (MIC> lOO^g/ml) against 54, 40 and 51% of the test strains of S. aureus, S. epidermidis and E. faecalis, respectively.
Effect of Various Factors on Antibacterial Activity
As shown in Table 6 , the decrease of the medium pH from 8 to 5 resulted in a 128-to 256-fold decrease of the observed activities of TE-031 and TE-032 against the Gram-positive bacteria. For EM over the same pH range, there was 1,024-to 2,(T48-fold decrease in measured activity. In addition, the activities of TE-031 and TE-032 against E. coli increased with an increase in the medium pH as well as EM. Like EMand JM, the MICs of TE-031 and TE-032 were slightly affected by changes in inoculum size between 105~109cfu/ml ( Table 7 ). The addition of horse serum to the medium, to provide a serum content of 20%, resulted in a 2-to 16-fold increase in the antibacterial activities of TE-031 and TE-032, as well as in that ofEM (Table 8) .
Time-kill Curve Studies The bactericidal activities of TE-03 1 and TE-032 against S. aureus Smith 4 and H. influenzae IID 984 were compared with those of EMand JM (Figs. 1 and 2) . At concentrations equal to the MIC, TE-031 and TE-032 did not cause a significant reduction in the number of viable cells during the first 8 hours Inoculum size: 106 cfu/ml.
Medium: Sensitivity Test Agar (Eiken). a Supplemented with 5% horse blood. Streptococcus pneumoniae IID 553a Inoculum size: 106 cfu/ml.
Medium: Sensitivity Test Agar (Eiken).
a %of horse serum supplemented. incubation of S. aureus. On the other hand, TE-031 was highly bactericidal against H. influenzae IID 984 as well as EM, showing dose-related killing kinetics; TE-031 caused a significant reduction (ca. 1/1,000) in the number of viable cells during the first 8hours at the concentration of MIC. Moreover, TE-031 and TE-032 inhibited the growth of S. aureus and H. influenzae at the concentrations of one to four times the MICafter 24 hours of incubation. In Vivo Therapeutic Activity Table 9 shows activities of TE-031, TE-032, EMand JM against experimental systemic infections provoked by S. aureus Smith 4, S. aureus BB, S. pyogenes J-l and S. pneumoniae IID 553 in mice. When administered orally, TE-031 was 6 to 15 times and 1 1 to 35 times more active than EMand JM, respectively; the ED50 values for TE-031 varied from 0.055 to 0.340mg/mouse against the test organisms. TE-032 was (A) MIC: 12.5jug/ml, (B) MIC: 12.5/xg/ml, (C) MIC: 6.25/ig/ml, (D) MIC: 12.5^g/ml. 4 to 9 times more potent than EMand equal to or 3-fold less potent than TE-031. As shown in Table  10 , TE-031 and TE-032 were approximately 5 and 7 times more active than EM, respectively, against the subcutaneous abscess infection with S. aureus BBin mice.
Pharmacokinetic Studies in Animals The plasma levels of TE-031 and TE-032, compared with EM, were measured after single po or iv administrations to mice, rats, rabbits or dogs. The peak concentration in plasma (Cmax), AUCand t1/2 are shown in Table ll . The Cmax and t1/2 values for TE-031 and TE-032 were 1-to 4-fold higher than those of EMafter po administration.
The AUCs for TE-031 and TE-032 were 5-to 10-fold greater than those ofEM. In addition, when administered intravenously, TE-03 1 demonstrated 2 to 3 times longer-lasting plasma levels as compared with EM.
Discussion
The biological properties of TE-031 and TE-032 have been compared with those of EM and JM in vitro and in vivo.
TE-031 and TE-032, having the same antibacterial spectrum as EM, have demonstrated an excellent in vitro activity against standard strains and clinical isolates, including aerobic and anaerobic Gram-positive bacteria and M. pneumoniae. In general, the in vitro potency of TE-031 against those organisms is equal to or greater than that of EM, whereas TE-032 is slightly less potent than EM. Among Gram-positive bacteria including S. aureus, S. epidermidis and E. faecalis, a significant number are resistant to TE-03 1 and TE-032 as well as to EM.
TE-031 and TE-032 are bactericidal against H. influenzae IID 984, but exert a bacteriostatic effect against S. aureus Smith 4.
Like EM, activities of TE-031 and TE-032 increased by the addition of serum to the medium but are not greatly affected by inoculum size. The higher decrease of the antibacterial activity in EM at the mediumpH 5, as compared with those in a Plasma levels were determined by bioassay method using Micrococcus luteus ATCC9341. b Drugs were administered orally (po) or intravenously (iv).
TE-031 and TE-032, can be explained by the differences of acid-stabilities among these drugs.4) The peak plasma levels of TE-031 and TE-032 are significantly higher than those of EMin several kinds of animals after the po or iv administrations of drugs.
Whenadministered orally, TE-031 and TE-032 exhibit several times more potent in vivo activity than EMagainst the systemic infection and the subcutaneous abscess infection in mice. The higher therapeutic efficacy provided by TE-031 and TE-032 in these models cannot be explained by differences in MICs, but may be related to the higher and longer-lasting plasma levels of both drugs.
Thus, 6-O-methyl derivatives of EMhave demonstrated excellent in vivo antibacterial activity and improved pharmacokinetic profiles: Especially, TE-03 1, which is more potent than TE-032, is interesting enough for further investigations.
